The World Health Organization’s Covax is feeling the strain from COVID-19 vaccine shortages; Argentina faces a new lockdown following a surge of COVID-19 cases; leronlimab ineffective against COVID-19.
A collaboration from the World Health Organization (WHO); Gavi, the Vaccine Alliance; and the Coalition for Epidemic Preparedness Innovations, Covax may be unable to meet its goal of supplying 20% of populations from the world’s 92 poorest countries with free COVID-19 vaccine doses by year-end as promised. Reported by The Wall Street Journal, despite deals with Pfizer, Moderna, Johnson & Johnson, and Novavax, Covax’s main supplier in India, the Serum Institute, is unable to export any doses at present, having been blocked by that country’s government, which wants to focus on vaccinating its citizens as it endures a surge of the deadly virus.
New coronavirus infections have topped 35,000 for 3 straight days in Argentina, accompanied by a skyrocketing number of deaths, reports The Associated Press. On Tuesday alone, there were 745 deaths and 35,543 new cases, breaking the nation’s previous daily records for both. The current lockdown will last through May 31, with President Alberto Fernández promising economic aid to areas affected by these new restrictions, as well as 4 million doses of the AstraZeneca and Sputnik V vaccines.
The monoclonal antibody leronlimab, from CytoDyn, failed to meet its primary end point or any of its secondary end points in 2 trials—CD10 and CD12—prompting the FDA to note that “data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19.” Data from CD10 show no difference in symptom resolution between the study and placebo groups, meaning both saw symptoms resolve no matter which agent they received, whereas in CD12 mortality rates from both groups were close to equal, at 20.5% in the leronlimab group and 21.6% in the placebo group.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More